Di Nicolantonio, Federica http://orcid.org/0000-0001-9618-2010
Vitiello, Pietro Paolo
Marsoni, Silvia http://orcid.org/0000-0002-5361-7122
Siena, Salvatore http://orcid.org/0000-0002-2681-2846
Tabernero, Josep http://orcid.org/0000-0002-2495-8139
Trusolino, Livio
Bernards, Rene http://orcid.org/0000-0001-8677-3423
Bardelli, Alberto http://orcid.org/0000-0003-1647-5070
Article History
Accepted: 1 March 2021
First Online: 16 April 2021
Competing interests
: P.P.V. has acted as a consultant of Biocartis and speaker for Merck. S.S. has acted as an advisor to Amgen, Bayer, BMS, Celgene, CheckmAb, Daiichi-Sankyo, Incyte, Merck, Novartis, Roche and Seattle Genetics. J.T. has acted as an advisor to Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Foundation Medicine, Genentech, HalioDX SAS, Menarini, Merck Serono, Merus, MSD, Novartis, Peptomyc, Pfizer, Roche, Roche Diagnostics, Sanofi, Seattle Genetics, Servier, and Taiho Pharmaceutical. L.T. has acted as a speaker for AstraZeneca, Eli Lilly and Merck KGaA, and has received research grants from Menarini, Merus, Pfizer, Servier and Symphogen. R.B. is an employee of and holds shares in Agendia, holds shares in Oncosence, and has received research funding from Astex and Eli Lilly. A.B. has acted as an advisor to Biocartis, Guardant, Horizon Discovery, Illumina, Inivata, Neophore, Roche and Third Rock, declares ownership interests (including patents) in Phoremost and Neophore, and has received commercial research grants from Neophore. The remaining authors declare no competing interests.